MedTrace Logo

A Comparative Sudy Comparing Argatroban® IV vs Desirudin SC for Suspected HIT With or Without Thrombosis Syndrome

NCT00787332 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2013-01-10

Study results available
· View outcomes & findings →

Summary

Compare Clinical Success and Costs in two Arms

Conditions

  • Suspected Heparin-Induced Thrombocytopenia

Interventions

DRUG

Desirudin or Argatroban®

Desirudin 15mg SC Argatroban® IV dosing per Package Insert

Sponsors & Collaborators

  • Canyon Pharmaceuticals, Inc.

    lead INDUSTRY

Principal Investigators

  • Dawn Bell, PharmD · Canyon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2009-12-31
Completion
2009-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00787332 on ClinicalTrials.gov